Quadrant Biosciences

We develop novel, saliva based tests for Autism, COVID-19 and Parkinson's.
Syracuse, 
NY
Investment type:
Equity
(Convertible Note)
Target raise:
$50,000
 - $1,070,000
Minimum investment:​
$100
End date:
Feb 22, 2021
Share
Share on facebook
Share on twitter
Share on linkedin
Share on email
Highlights

  • Applied our expertise in RNA analysis to co-develop FDA authorized COVID-19 saliva test with SUNY.
  • Developed & commercialized world’s first saliva based epigenetic test for autism spectrum disorder.
  • Sales from our new saliva COVID-19 tests have exceeded $6.5MM to date since September 2020.
Our Story

We develop epigenetic saliva biomarkers including the world's first saliva test for autism. We recently received FDA emergency use authorization for a COVID-19 saliva test, and are currently working on developing tests for Parkinson's disease, concussion, and Anorexia nervosa.
Our Ambition

Our goal is to have the Clarifi epigenetic diagnostic tests become the standard of care, positively impacting millions of people across the globe. We also want to be on the forefront of RNA analysis and continue to contribute to the fight against RNA viruses such as COVID-19.